Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
Jan 8
Johnson & Johnson and Merck on Monday
announced plans to buy cancer therapy developers on the first
day of a major U.S. healthcare conference, igniting what
industry participants hope will be a strong year for deals after
a solid end to 2023.
Deals announced on Monday had a combined equity value of
more than $6 billion, including one by medical device maker
Boston Scientific BSX.N for Axonics Inc AXNX.O . That follows
roughly $25 billion worth of U.S.-listed biotech deals last
month, according to data provider LSEG Deals Intelligence.
Meanwhile, over 8,000 people are gathering at the JPMorgan
healthcare conference in San Franscisco, in another sign of a
return to business as usual after the COVID-19 pandemic.
Global pharma companies' efforts to replace revenue from
older drugs with promising new ones were largely stymied in
2023, but looming patent expirations and easing financing costs
are setting up 2024 well, industry sources say.
On Monday, J&J JNJ.N said it would buy Ambrx Biopharma
AMAM.O for $2 billion to gain promising targeted cancer
therapies known as antibody drug conjugates (ADC).
The deal gets "the ball rolling on what seems to be a strong
start for M&A in 2024", said Citi analyst Joanne Wuensch.
Interest in these drugs has spiked and several related
companies have been acquired in recent months, including
ImmunoGen IMGN.O by AbbVie ABBV.N and Seagen by Pfizer
PFE.N .
Separately, Merck MRK.N said it would buy cancer drug
developer Harpoon Therapeutics HARP.O for about $680 million,
gaining access to early-stage immunotherapies being tested for
lung cancer and multiple myeloma.
Certainly we know the Pharma mega caps have cash to spend and pipelines to rebuild.
KR
ZA
Nick Glover's MEI Pharma Inc are listed on Nasdaq so probably not him or them.
Either way a cracking start to the year, also pushes the price significantly higher than Riverfort's last subscription price (around .59p). So one would expect that they would sell into the rise. This will mean that they'll not receive additional shares, which is a big plus.
I'd also assume that they have sold some of their recent subscription recently too.
KR
ZA
HAPPY NEW YEAR
RNS Number : 2722Y
Sareum Holdings PLC
02 January 2024
Sareum Holdings PLC
("Sareum" or the "Company")
Development and commercialisation licence for SRA737
Cambridge, UK, 2 Jan 2024 - Sareum Holdings plc (AIM: SAR), a clinical-stage biotechnology company developing next-generation kinase inhibitors for autoimmune disease and cancer, today announces that the Company's co-development partner, the CRT Pioneer Fund ("CPF"), has entered into a development and commercialisation licence agreement for SRA737 (the "Licensing Agreement") with a private biopharma company based in the United States (the "Licensee Company").
Under the terms of the Licensing Agreement, an immediate upfront payment of US$0.5 million is due to CPF. An additional fee made up of up to US$1.0 million cash and 500,000 shares in the Licensee Company (the "Consideration Shares") may be payable upon the sooner of 12 months following the signing of the Licensing Agreement, or the event of the Licensee Company achieving certain commercial and material financing objectives. A further announcement regarding any future income, including any Consideration Shares which may be issued, will be made at the appropriate time.
Additional payments to the aggregate amount of up to US$289 million may become payable to CPF under the Licensing Agreement, subject to achievement of certain development, regulatory and commercial milestones which may or may not be achieved. The Licensee Company will also pay tiered high single digit royalties to CPF on the net sales of any product successfully developed and commercialised.
Under the terms of Sareum's co-development agreements with CPF and Cancer Research Technology Ltd, Sareum is entitled to receive 27.5% of any income arising from this licensing of the SRA737 programme. Therefore, Sareum is entitled to receive US$137,500 from the upfront fee payable under the Licensing Agreement, as well as 27.5% of any future payments payable by the Licensee Company (including any Consideration Shares received), under the terms of the Licensing Agreement.
Dr Tim Mitchell, CEO of Sareum, commented: "SRA737 has shown considerable promise in earlier clinical studies, demonstrating a robust safety profile and preliminary efficacy, in particular in combination with low dose chemotherapy. With CPF, we are very pleased a partner has been identified to advance this exciting molecule into further development and believe this licensing agreement offers the best path forward for SRA737.
KR
ZA
Unfortunately I'm incapacitated my sciatica has me all but bed bound so I'll not be at the AGM.
Given the lack of anything of substance on the rns that will drive the share price higher, I don't even feel like listening in online. I wanted to see the board face to face.
Have a good day those attending, I'll probably sign off from the board until next year, although it may be a tad early early to wish all seasons greetings.
Catch up in 2024
KR
ZA
ZA
Bid has moved up,
Dummy trades to sell are higher than yesterday, so as it stands it's blue, appreciate there's potentially 500,000+ shares to sell.
However, if Riverfort "dump" shares it makes their warrants less valuable.
Their initial warrants were £1.40 on the first £2mn subscription (happy to be corrected if this incorrect).
If the price collapses then they potentially optimise their investment.
Whilst they can't lose, I'm sure they would prefer to win big.
A few weeks away from the AGM. We'll get a clearer indication sooner rather than later how this will play out.
KR
ZA
RNS
Exercised options, they did retain some shares and didn't sell them all through.
RNS Number : 8299S
Sareum Holdings PLC
08 November 2023
Sareum Holdings PLC
("Sareum" or the "Company")
Director Dealings
Cambridge, UK, 8 November 2023 - Sareum Holdings plc (AIM: SAR), a biotechnology company developing next generation kinase inhibitors for autoimmune disease and cancer, announces the following share transactions carried out by Directors.
As announced on 2 November 2023, Dr Tim Mitchell, Chief Executive Officer, and Dr John Reader, Chief Scientific Officer, each exercised options over 95,040 ordinary shares of 1.25 pence each in the Company (the "Options Exercise"), at an exercise price of 30 pence per ordinary share.
Of those shares received pursuant to the Options Exercise, Dr Mitchell and Dr Reader have retained 23,040 and 44,614 ordinary shares, respectively, following the sale of 72,000 and 50,426 ordinary shares, respectively, at a price of 56.8 pence per ordinary share (the "Share Sales"). The Share Sales were undertaken partly in order to compensate for the cost and tax liabilities arising from the Options Exercise.
Following the Options Exercise and Share Sales, Dr Mitchell's and Dr Reader's resultant interests in the Company will be as follows:
Director/ Number of Number of Sale Resultant Percentage
PDMR shares purchased shares sold price total number of issued
pursuant to pursuant of ordinary share capital
the Options to Sale Shares shares held
Exercise in the Company
T im Mitchell
(1) 95,040 72,000 56.8p 1,032,561 1.47%
------------------ ---------------- -------- ---------------- ---------------
J ohn Reader
(2) 95,040 50,426 56.8p 1,077,111 1.53%
------------------ ---------------- -------- ---------------- ---------------
(1) - Included within Tim Mitchell's total holding are 200,000 ordinary shares held by his spouse.
(2) - Included withing John Reader's total holding are 66,666 ordinary shares held by his spouse.
For further information, please contact:
Sareum Holdings plc
Tim Mitchell, CEO 01223 497700
KR
ZA
Hi PCS
As per Andy the train strike de-railed my plans last year.
Will be looking to attend, I also share the same view re the board will want to pull a rabbit out of the hat before the AGM.
It's been a disappointing last couple of years.
Ether way given the amount I still have across various accounts SIPP included, a face to face chat with the board and other shareholders is pencilled in.
KR
ZA
Hi Warty
Glad to see you "keeping the faith"
I remember the shenanigans below from 2012 very well
Finally a management gem from the archives:-
"On 19 July 2012, the Company issued a Trading Update stating that it expects to conclude a commercial deal with at least one of its research programmes by the end of the calendar year, and the Company stands by that statement."
It's shaped SAR's comms forever more.
Ultra cautious and conservative which I prefer to some of the "cowboys/ crooks" we've seen on AIM over the years.
It's been a tough hold the last few years but the irony for me is strategically we're in as positive position as I can recall.
2 fully owned compound 1 already post clinical
27.5% share in a phase 2a asset just waiting for news.
Funded through to phase 1b (controversial as it was). It's done and can't be undone unless there's some "TRANSFORMATIONAL" news.
Share price pain aside I'm positive (some might say deluded) .
I'm retired early 50's thanks to SAR. I hope a few more of you will join me in retirement IA shortly.
KR
ZA
Hi Matty
Our " numbers" are almost identical.
I was 32, my mum passed away aged 57.
My dad hasn't remarried, he's in his mid 80's, now that he's in remission, (by the grace of God), he's in remarkably good shape both mentally and physically for someone of his age.
It's been a blessing in my eyes that we've been able to look after him these last few months, and watch him get back to his old self.
KR
ZA
Hi Matty
I couldn't agree more.
Having lost my mother to cancer when she was in her 50's was our first brush with cancer.
We'd never known anyone else who had cancer so we fairly naïve to all of the situations that we could've arisen.
A long story short she passed away 6 months to the day after her missed diagnosis. She had gone to the doctors many times but they were fairly dismissive. Unfortunately she was too weak for an operation and Chemo only added to her suffering.
20+ years later (earlier this year) my dad had a tumour successfully removed and is in remission.
He's in his 80's and we see every day we have with him as a blessing.
Only when I became a parent could I appreciate what my parents did for me. Having come to the UK in the 60's it was easy and I know I'll never be able to repay their debt as parents.
HBD - cherish your parents for as long as you can
KR
ZA